Skip to main content
. Author manuscript; available in PMC: 2012 Nov 28.
Published in final edited form as: Cancer Lett. 2011 Jul 1;310(2):148–159. doi: 10.1016/j.canlet.2011.06.029

Fig. 3. Expression of mTRAIL by NSCs.

Fig. 3

A. Control and NSCs-mTRAIL were analyzed for TRAIL mRNA expression by PCR of cDNA with a pair of specific primers. B-Surface expression of mTRAIL by NSCs was evaluated by flow cytometry. C. Quantitative measurement of mTRAIL expression in NSCs was analyzed in plate ELISA. D. Effect of bortezomib on toxicity of NSCs was studied using membrane integrity permeability assay. E–F. Changes in the expression of mTRAIL in NSCs-mTRAIL cells treated with bortezomib for 24 hours at mRNA (E) and protein level (F) analyzed by RT-PCR and quantitative ELISA. Data are shown as mean±SD, * p<0.05.